Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 03 July 2017 | By Zachary Brennan
UK health minister Jeremy Hunt and business minister Greg Clark on Monday wrote a letter to the Financial Times calling for the UK to continue working with the European Medicines Agency after Brexit.
According to the Times, the letter said: "we want deep, broad and dynamic co-operation, and in this context the UK would like to find a way to continue to collaborate with the EU, in the interests of public health and safety."
The move was widely praised by UK industry groups and follows the UK government’s EU External Affairs Subcommittee in March noting that there may be "significant benefits” in continuing UK participation in the EMA.
But even if the UK negotiates a system whereby they can continue to work with EMA, the UK will lose the benefit of hosting EMA’s headquarters to another European city. Next November, EU member states will vote on where EMA will relocate from London.
The EMA and European Commission have also released guidance to prepare industry for the UK’s withdrawal from the EU.
Tags: Brexit, Jeremy Hunt, EMA post-Brexit